title: Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina.
abstract: BACKGROUND
  Late stent thrombosis (LST) after sirolimus-eluting stent (SES) implantation has been demonstrated previously. Although incomplete neointimal coverage after SES implantation has been reported, local long-term hypercoagulability remains unknown.
  
  
  METHODS
  We evaluated the local persistent coagulative response in eighty-three consecutive patients with stable angina, treated with either SES (n=51) or BMS (n=32) implantation for isolated de novo left anterior descending (LAD) stenosis. We measured prothrombin fragment F1+2 (frF1+2) and D-dimer levels sampled in the coronary sinus (CS) and sinus of Valsalva (V). The transcardiac gradient (Δ) was defined as the CS level minus V level.
  
  
  RESULTS
  The ΔfrF1 + 2 and ΔD-dimer were significantly greater in the SES group than in the BMS group (0.50 ± 0.35 vs -0.14 ± 0.15 nmol/l, p=0.009 and 0.24 ± 0.21 vs -0.05 ± 0.16 μg/ml, p=0.041, respectively). We selected the hypocoagulative [ΔfrF1 + 2<0.15 (mean value-SD) nmol/l, n=21] and hypercoagulative [ΔfrF1 + 2>0.85 (mean value+SD) nmol/l, n=14] groups out of the SES patients. Multivariate analysis was performed to identify independent predictors of local hypercoagulability. Total SES length was the only independent predictor of local hypercoagulability. There was a significant positive correlation between the ΔfrF1 + 2 and total stent length in the SES group (r=0.57, p<0.05).
  
  
  CONCLUSIONS
  An increased local coagulative response was observed in the convalescent phase after SES implantation as compared to BMS. Careful long-term follow-up of patients after longer SES implantation is recommended in order to avoid LST.
authors.affiliation: Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima, Japan. yamakoji3@hotmail.com
authors.forename: Koji
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Tetsuzo
authors.initials: T
authors.lastname: Wakatsuki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Niki
authors.forename: Kenya
authors.initials: K
authors.lastname: Kusunose
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Koshiba
authors.forename: Shusuke
authors.initials: S
authors.lastname: Yagi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Taketani
authors.forename: Takashi
authors.initials: T
authors.lastname: Iwase
authors.forename: Noriko
authors.initials: N
authors.lastname: Tomita
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Yamada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Soeki
authors.forename: Masashi
authors.initials: M
authors.lastname: Akaike
authors.forename: Masataka
authors.initials: M
authors.lastname: Sata
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000503:physiopathology* / Q000628:therapy*; D015331:Cohort Studies; D003328:Coronary Thrombosis / Q000209:etiology / Q000503:physiopathology; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D019851:Thrombophilia / Q000209:etiology / Q000503:physiopathology*; D013997:Time Factors
chemical_list: D020123:Sirolimus